PathAI Doesn't Have a Free Plan — Here's What It Costs

⚡ Quick Verdict

No free plan. The cheapest way in is paid plan at Custom quote; no public list price. Consider free alternatives in the automation & workflows category if budget is tight.

See Pricing →See Plans ↓

Who Should Pay for This

👤

Best For

✓Established business
✓Budget for premium tools
✓Need automation & workflows features
✓Professional use case
✓Want official support

What Users Say About PathAI

👍 What Users Love

✓AISight Dx has FDA clearance for primary diagnosis in the United States and is CE-IVD marked for primary diagnosis in the EEA, UK, and Switzerland.
✓Designed for enterprise digital pathology workflows, including case management, image management, workflow tools, and access to AI applications from a central cloud-native platform.
✓Strong biopharma orientation, with products and services for biomarker discovery, histology assessment, drug development, and clinical trial endpoint standardization.
✓Large pathology data and expertise base, including a stated network of 450+ board-certified pathologists and 32.5M+ contributed annotations used to support algorithm development and validation.
✓Broad AI product menu covering areas such as PD-L1, HER2, ER, PR, Ki-67, MASH, inflammatory bowel disease, tumor cellularity, artifact detection, and tumor microenvironment analysis.
✓Recent large-scale partnerships, including Labcorp's expanded deployment of AISight Dx and MedStar Health's partnership to deploy AISight Dx and advanced AI applications.

👎 Common Concerns

⚠Pricing is not public, so laboratories and sponsors must engage sales to understand total cost, implementation scope, and contract structure.
⚠Several PathAI algorithms are explicitly described as Research Use Only in the United States and not for diagnostic procedures, which limits direct clinical diagnostic use cases.
⚠Deployment depends on digital pathology infrastructure such as slide scanners, image workflows, validation processes, and lab change management.
⚠AISight Dx scanner support is specific; PathAI lists FDA-cleared use with Hamamatsu NanoZoomer S360MD and Leica Aperio GT 450 DX scanners.
⚠The platform is specialized for pathology organizations and biopharma teams, making it a poor fit for general healthcare AI automation, patient engagement, or routine clinical note-taking.

Frequently Asked Questions

What is PathAI used for?

PathAI is used for AI-powered digital pathology workflows, including image management, case management, biomarker analysis, clinical trial histology assessment, tumor microenvironment analysis, and AI-assisted pathology research.

Is PathAI FDA-cleared?

PathAI states that AISight Dx, its digital pathology image management system, is FDA-cleared for primary diagnosis in the United States. Many individual PathAI algorithms are listed as Research Use Only in the United States and not for diagnostic procedures.

Who is PathAI best suited for?

PathAI is best suited for anatomic pathology laboratories, academic medical centers, reference laboratories, health systems, central labs, and biopharma companies working on biomarker discovery, clinical trials, or digital pathology transformation.

Does PathAI publish pricing?

No public self-serve pricing is listed on the website. PathAI uses enterprise pricing based on deployment needs, platform scope, AI products, services, and clinical trial or laboratory requirements. Buyers need to request a quote from PathAI sales for exact contract pricing.

Can PathAI replace a pathologist?

The website presents PathAI as AI-powered pathology technology intended to support pathology workflows, improve histology assessment, and assist research or clinical trial processes. It does not describe the platform as replacing pathologists.

Ready to Get Started?

See PathAI plans and find the right tier for your needs.

See Pricing Plans →

Still not sure? Read our full verdict →

More about PathAI

Pricing Review Alternatives Pros & Cons Worth It?Tutorial

📖 PathAI Overview 💰 PathAI Pricing & Plans ⚖️ Is PathAI Worth It?🔄 Compare PathAI Alternatives

Last verified March 2026

What Users Say About PathAI

👍 What Users Love

✓AISight Dx has FDA clearance for primary diagnosis in the United States and is CE-IVD marked for primary diagnosis in the EEA, UK, and Switzerland.
✓Designed for enterprise digital pathology workflows, including case management, image management, workflow tools, and access to AI applications from a central cloud-native platform.
✓Strong biopharma orientation, with products and services for biomarker discovery, histology assessment, drug development, and clinical trial endpoint standardization.
✓Large pathology data and expertise base, including a stated network of 450+ board-certified pathologists and 32.5M+ contributed annotations used to support algorithm development and validation.
✓Broad AI product menu covering areas such as PD-L1, HER2, ER, PR, Ki-67, MASH, inflammatory bowel disease, tumor cellularity, artifact detection, and tumor microenvironment analysis.
✓Recent large-scale partnerships, including Labcorp's expanded deployment of AISight Dx and MedStar Health's partnership to deploy AISight Dx and advanced AI applications.

👎 Common Concerns

⚠Pricing is not public, so laboratories and sponsors must engage sales to understand total cost, implementation scope, and contract structure.
⚠Several PathAI algorithms are explicitly described as Research Use Only in the United States and not for diagnostic procedures, which limits direct clinical diagnostic use cases.
⚠Deployment depends on digital pathology infrastructure such as slide scanners, image workflows, validation processes, and lab change management.
⚠AISight Dx scanner support is specific; PathAI lists FDA-cleared use with Hamamatsu NanoZoomer S360MD and Leica Aperio GT 450 DX scanners.
⚠The platform is specialized for pathology organizations and biopharma teams, making it a poor fit for general healthcare AI automation, patient engagement, or routine clinical note-taking.